Immatics (IMTX) Cash from Financing Activities (2019 - 2025)
Immatics (IMTX) posted Cash from Financing Activities of $115.9 million for Q4 2025, up 13604.66% sequentially from -$858086.4 in Q3 2025, and down 25.91% YoY from $156.4 million in Q4 2024.
Immatics (IMTX) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Immatics has reported Cash from Financing Activities for 7 years, with the latest figure at $115.9 million in Q4 2025.
- Quarterly Cash from Financing Activities fell 25.91% year-over-year to $115.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $113.4 million (down 67.09% YoY) and the FY2025 annual result came in at $110.0 million, down 68.21% from the prior year.
- Cash from Financing Activities advanced to $115.9 million in Q4 2025 per IMTX's latest filing, from -$858086.4 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $189.7 million in Q1 2024 and troughed at -$1.0 million in Q4 2023.
- A 5-year average of $33.7 million and a median of -$639942.7 in 2021 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2021 and 2024: Cash from Financing Activities slumped 482.48% in 2021, then soared 20511.49% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$670367.0 in 2021, then jumped by 16154.62% to $107.6 million in 2022, then plunged by 100.97% to -$1.0 million in 2023, then soared by 15054.62% to $156.4 million in 2024, then slipped by 25.91% to $115.9 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $115.9 million, -$858086.4, and -$822934.7 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | 115.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 115.88 Mn |
| Dec 31, 2025 | 115.88 Mn |
| Sep 30, 2025 | -858,086.44 |
| Sep 30, 2025 | -858,086.44 |
| Jun 30, 2025 | -822,934.69 |
| Jun 30, 2025 | -822,934.69 |
| Mar 31, 2025 | -775,238.83 |
| Mar 31, 2025 | -775,238.83 |
| Dec 31, 2024 | 156.40 Mn |
| Dec 31, 2024 | 156.40 Mn |
| Sep 30, 2024 | -826,959.29 |
| Sep 30, 2024 | -826,959.29 |
| Jun 30, 2024 | -609,518.37 |
| Jun 30, 2024 | -609,518.37 |
| Mar 31, 2024 | 189.73 Mn |
| Mar 31, 2024 | 189.73 Mn |
| Dec 31, 2023 | -1.05 Mn |
| Dec 31, 2023 | -1.05 Mn |
| Sep 30, 2023 | 54.32 Mn |
| Sep 30, 2023 | 54.32 Mn |